ORIGINAL ARTICLE

Cell Research (2008): 281-289
© 2008 IBCB, SIBS, CAS All rights reserved 1001-0602/06 $ 30.00
www.nature.com/cr

Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression

Guogen Mao¹, Fenghua Yuan¹, Kimberly Absher², C Darrell Jennings², Dianna S Howard³, Craig T Jordan⁴ and Liya Gu^1,2

Correspondence: Liya Gu Tel: +1-859-323-0285; Fax: +1-859-323-1059 E-mail: lgu0@email.uky.edu

Download as printable (PDF) file Full Text (html)file Search Medline for articles by: Qiang Chen

Acute myeloid leukemia (AML) is an aggressive hematological cancer. Despite therapeutic regimens that lead to complete remission, the vast majority of patients undergo relapse. The molecular mechanisms underlying AML development and relapse remain incompletely defined. To explore whether loss of DNA mismatch repair (MMR) function is involved in AML, we screened two key MMR genes, MSH2 and MLH1, for mutations and promoter hypermethylation in leukemia specimens from 53 AML patients and blood from 17 non-cancer controls. We show here that whereas no amino acid alteration or promoter hypermethylation was detected in all control samples, 18 AML patients exhibited either mutations in MMR genes or hypermethylation in the MLH1 promoter. In vitro functional MMR analysis revealed that almost all the mutations analyzed resulted in loss of MMR function. MMR defects were significantly more frequent in patients with refractory or relapsed AML compared with newly diagnosed patients. These observations suggest for the first time that the loss of MMR function is associated with refractory and relapsed AML and may contribute to disease pathogenesis.

Cell Research (2008) 18:281-289. doi: 10.1038/cr.2008.14; published online 29 January 2008

Keywords: leukemia relapse, MSH2, MLH1, hypermethylation